This trial aims to assess the safety and effectiveness of avelumab, a targeted therapy, in patients that are previously untreated for high risk stage 2, stage 3 and stage 4 Hodgkin lymphoma .
This trial is treating patients with Hodgkin Lymphoma.
This is a systemic therapy.
You may be able to join this trial if:
- You are currently receiving treatment for your cancer.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study
Other Non-Commercial Sponsor
University College, London
Eligible patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles. Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab intravenously, every 2 weeks.
Not Recruiting Hospitals Read More